DRUG
Growth Hormone
Growth hormone (Norditropin, Novo nordisk) was administrated on day 6 of HMG stimulation daily in a dose of 2.5 mg S.C. till the day of hCG administration.
Status
Completed
Phase
Phase 4
Enrollment
141
Locations
1
Results
Not posted
Publications
1
Study summary
What the protocol is testing.
The effect of use of the growth hormone with antagonist protocol on the outcome of the IVF/ICSI cycles in poor responders.
Full detailed description
Two groups of poor responder female patients planned to receive the antagonist IVF/ICSI protocol are randomized to whether or not to add growth hormone to their protocol.
Interventions
Treatment arms and agents.
Timeline
From registration to results.
First posted
Jul 21, 2014
Study start
Jul 2014
Primary completion
Jul 2015
Study completion
Jul 2015
Results posted
Not reported
Registry updated
Nov 11, 2021
Outcomes
What the study measures.
Primary outcomes
Live birth rate
Time frame · Up to 9 months
Secondary outcomes
Clinical pregnancy rate
Time frame · Up to 5 weeks
Eligibility
Who can take part.
- Minimum age
- 20 Years
- Maximum age
- 45 Years
- Sex
- FEMALE
- Healthy volunteers
- No
Inclusion Criteria: * females fulfilling the criteria of the ESHRE consensus 2011: * at least two of the following three features must be present: * dvanced maternal age (≥40 years) or any other risk factor for POR * previous POR (≤3 oocytes with a conventional stimulation protocol) * an abnormal ovarian reserve test (i.e. AFC ,5-7 follicles or AMH ,0.5 -1.1 ng/ml). Exclusion Criteria: * women who suffer from any other cause of infertility other than poor ovarian reserve * refusal of the patient to consent for using her data in the study.
Study locations
1 registered sites.
Egypt. Showing up to 24 locations stored in the fast local snapshot.
Kasr Al Aini
Cairo, Egypt
Related trials
More studies on Cetrorelix.
NCT IDStudyPhase / statusEnrollmentUpdated
Drospirenone-Primed Ovarian Stimulation Versus GnRH Antagonist Protocol in Poor Ovarian Responders Undergoing Freeze-All IVF/ICSI
Ahmed Saad · Poor Ovarian Reserve · Infertility (IVF Patients)
Phase 1 / Phase 2
Not yet recruiting
100
2026-07
Oral GnRH Antagonist (Linzagolix) Versus Injectable GnRH Antagonist for Ovarian Stimulation in IVF/ICSI
Centro A.M.B.R.A. (Associazione Medici e Biologi per la Riproduzione Assistita) · Infertility, Female · Ovulation Induction
Early Phase 1
Not yet recruiting
189
2026-07
A Study to Compare the Efficacy and Safety of Follitropin Alfa/Lutropin Alfa Versus hMG in Japanese Participants With LH and FSH Deficiency Undergoing ART (HINATA)
Merck Healthcare KGaA, Darmstadt, Germany, an affiliate of Merck KGaA, Darmstadt, Germany · Infertility
Phase 3
Recruiting
266
2026-07
Serum FSH Monitoring for Identification of an Optimal Range During Ovarian Stimulation
ART Fertility Clinics LLC · Ovarian Stimulation
Not applicable
Recruiting
150
2026-06
Dydrogesterone Versus GnRH Antagonist in Poor Responders Undergoing Double Ovarian Stimulation
Bedaya Hospital · Infertility
Phase 2
Recruiting
120
2026-05
Progesterone Primed Protocol Versus GnRH Antagonist in With PCO Undergoing ICSI
Beni-Suef University · IVF · PCO
Phase 2 / Phase 3
Completed
200
2026-04
NATural Ovarian Stimulation
Assistance Publique - Hôpitaux de Paris · Infertility
Phase 4
Completed
129
2026-04
Preservation of Fertility by Ovarian Stimulation Associated With Tamoxifen, Prior Chemotherapy for Breast Cancer
Institut Cancerologie de l'Ouest · Breast Cancer
Phase 2
Active, not recruiting
102
2026-03
Related PeptideStat pages
Put the record in context.
Research pages describe evidence. Vendor pages, where available, describe independently tracked research-product listings and are not clinical recommendations.